a Department of Dermatology , University of Rome "Tor Vergata" , Rome , Italy.
b Dermatology, Department of Clinical Sciences and Translational Medicine, International Medical School , University of Rome "Tor Vergata" , Rome , Italy.
Postgrad Med. 2019 Apr;131(3):239-240. doi: 10.1080/00325481.2019.1575613. Epub 2019 Feb 8.
Treatment of psoriasis and psoriatic arthritis in patients with concomitant chronic, severe viral infections, particularly HIV or HBV, represents a challenge, due to contraindication to conventional immunomodulating systemic drugs and biologics, including anti-TNF alpha, anti-IL12/23, and anti-IL17 agents. Recently, apremilast, a selective inhibitor of phosphodiesterase E4 has been suggested to be a safe and effective therapeutic option in HIV-infected population with psoriatic arthritis. We report the case of a patient with psoriatic arthritis and concomitant HIV and HBV infection successfully treated with apremilast.
治疗同时患有慢性、严重病毒感染（尤其是 HIV 或 HBV）的银屑病和银屑病关节炎患者颇具挑战，因为这些患者禁忌使用传统的免疫调节全身药物和生物制剂，包括抗 TNF-α、抗 IL-12/23 和抗 IL-17 药物。最近，磷酸二酯酶 E4 的选择性抑制剂阿普米司特被认为是 HIV 感染合并银屑病关节炎患者的一种安全有效的治疗选择。我们报告了一例同时患有银屑病关节炎和 HIV、HBV 感染的患者，成功地使用阿普米司特进行了治疗。
